The proposed MCIDs and composite measure provide a standardized way to assess clinically relevant cognitive changes in preclinical Alzheimer's disease trials.
Our MCIDs may be applied in clinical practice or clinical trials for identifying whether a clinically relevant change has occurred. The composite measure can be useful as a clinically relevant cognitive test outcome in preclinical AD trials.
Borland et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: